Tag: mdcIRMTEV46000
MedinCell partner Teva confirms expecting US approval and commercialization of mdc-IRM/TEV46000 in the first half of 2023 – 07/27/2022 at 20:00
Kåre Schultz, Chairman and CEO of Teva, spoke today during the presentation of the results for the second quarter of 2022. Responding to questions from attendees, Schultz said, “We are…